403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Medicenna Therapeutics Corp.
(MENAFN- Baystreet) 09:55 AM EST - Medicenna Therapeutics Corp.: Announced that the first patient has been dosed in the NEO-CYT study, a randomized, investigator-initiated neoadjuvant Phase 1b trial evaluating MDNA11, Medicenna's long-acting,“beta-enhanced not-alpha” IL-2 Superkine, in combination with nivolumab, with or without ipilimumab, in patients with high-risk, surgically resectable Stage III cutaneous melanoma at up to 12 centers in Italy. Medicenna Therapeutics Corp.
shares T are trading unchanged at $0.66.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment